This study describes the design, synthesis, and biological evaluation of a series of novel small molecule GPR119 agonists with improved potency and moderate physi- 
| INTRODUCTION
G protein-coupled receptors (GPCRs) are a superfamily of seven transmembrane receptors (7-TM) with almost 800 protein members. By binding to numerous different extracellular ligands, they transmit different information to signaling pathways inside the cell. [1, 2] G protein-coupled receptor 119 (GPR119), as a member of the class A (rhodopsin-type) GPCR family, is highly expressed on only a limited number of tissues, such as pancreatic β-cells and enteroendocrine cells of the gastrointestinal tract in humans. [3, 4] The activation of GPR119 has the stimulatory effects of glucose-dependent insulin secretion in pancreatic β-cells as well as intestinal secretion of incretin hormones including glucose-dependent insulinotropic peptide and glucagon-like peptide 1, which leads to regulation of glucose homeostasis and improvement of glucose control. [5] Based on these findings, pharmaceutical industry had shown great interest in GPR119 receptor as a promising therapeutic target for type 2 diabetes mellitus (T2DM). [6] [7] [8] Several phospholipids and lipid amides such as lysophosphatidylcholine, oleoylethanolamide, and oleoyldopamine have been identified as endogenous GPR119 agonists. However, due to the low activity and poor selectivity of these endogenous agonists at GPR119 receptor in cellular assays, many synthetic small molecule GPR119 agonists have been disclosed over the past several years. [9] [10] [11] For example, AR231453 from Arena Pharmaceuticals and PSN632408 from Prosidion Ltd were two of the earlier potent and orally efficacious GPR119 agonists with significant published preclinical data. However, owing to the loss of efficacy as well as indicate tachyphylaxis, the positive results obtained in preclinical studies did not appear in the phase II clinical trials, which brought uncertainty to the clinical prospects of GPR119 agonists for the treatment of T2DM. [12] [13] [14] Following the initial enthusiasm, more and | ZHOU et al.
more novel GPR119 agonists with diverse chemical structures have been patented and reported, some of which were also under clinical trials, as shown in Figure 1 . [15] Many of the disclosed chemical structures share a common structural motif including an aryl or heteroaryl group linked via a space group to a piperidine moiety capped with a carbamate or heterocycle group. From previous studies, we learned that the piperidine scaffold played an important role for bioactivity, as well as the methylsulfonylphenyl fragment. [16, 17] In this study, we chose the pyridine derivative GSK-1292263 as a lead structure, kept the active pharmacophores, and replaced the heterocycle for further structural modification, which led to new pyridine analogs, as shown in Figure 2 , for the purpose of searching for novel GPR119 agonists with pharmacological superiority. Herein, we reported the synthesis, biological evaluation, and structure-activity relationship of a series of novel pyridine analogs as small molecule GPR119 agonists for the treatment of T2DM.
| METHODS AND MATERIALS

| Chemistry
All chemicals were reagent grade and used as purchased. All reactions were performed using distilled dry solvent. Column chromatography (CC) was carried out using silica gel 60 100-200 mesh. 
| Synthesis of 2-(4-(methylsulfonyl) phenyl)-5-(piperidine-4-yloxy)pyridine (compound 4)
Trifluoroacetic acid (5 ml) was added to a solution of compound 3 (4 g, 9.28 mmol) and dichloromethane (20 ml). The reaction mixture was stirred and refluxed for 30 min. After completion of the reaction monitored by TLC, the mixture was cooled to room temperature and the solvent was removed in vacuo. The residue was dissolved in water (30 ml), basified with aqua ammonia (3 ml) to pH 9-10, filtered, and washed with water (30 ml × 2) to afford white solid compound 4 (2.74 g, 89% 
| Synthesis of compound 5-13
Methyl carbonochloridate (27.4 mg, 0.29 mmol) was added dropwise slowly into a solution of compound 4 (79.7 mg, 0.24 mmol), NaOH (19 mg, 0.48 mmol), THF (8 ml), and water (4 ml) at 0°C. The mixture was then reacted at room temperature for 1.5 hr. TLC monitoring showed complete consumption of starting material. THF was removed in vacuo, and then the residue was extracted twice with a mixture of ethyl acetate (50 ml) and water (25 ml). The organic phases were collected, washed twice with saturated sodium chloride solution (100 ml), dried over anhydrous sodium sulfate, evaporated under diminished pressure to give white solid Compounds 6-13 were prepared in a manner similar to that described for compound 5. Detailed analytical data are given in Supporting Information.
| Synthesis of compound 14
A mixture of compound 4 (99.6 mg, 0.3 mmol), benzyl bromide (45.36 mg, 0.36 mmol), trimethylamine (45.45 mg, 0.45 mmol), and dichloromethane (20 ml) was stirred at room temperature overnight. After completion of the reaction monitored by TLC, the mixture was extracted with dichloromethane (30 ml) and water (20 ml), washed twice with saturated sodium chloride solution (20 ml), dried over anhydrous sodium sulfate, evaporated in vacuo to give white solid compound 14 (48.1 mg, 38% 
| Synthesis of compound 15-18
A mixture of compound 4 (99.6 mg, 0.3 mmol), 2-chloropyrimidine (41 mg, 0.36 mmol), cesium carbonate (0.2 g, 0.6 mmol), and acetone (15 ml) was stirred at 50°C overnight. TLC monitoring showed complete consumption of starting material. After completion of the reaction, the mixture was cooled to room temperature, and the solvent was removed under diminished pressure. The residue was purified by CC (petroleum ether/EtOAc = 10/1) to give white solid compound 15 (40.6 mg, 33%). 
| Synthesis of compound 19-20
A mixture of compound 4 (199.2 mg, 0.6 mmol), sodium hydride (27.6 mg, 1.2 mmol), and dimethyl formamide (20 ml) was stirred at 100°C for 1 hr. Then, 2-chloro-5-fluoropyrimidine (95.04 mg, 0.72 mmol) was added into the mixture and stirred at 100°C overnight. After completion of the reaction monitored by TLC, the mixture was extracted with ethyl acetate (30 ml) and water (20 ml), washed twice with saturated sodium chloride solution (20 ml), dried over anhydrous sodium sulfate, evaporated in vacuo to give white solid compound 19 (102.7 mg, 40%). 1 
| In vitro GPR119 agonist activity
Intracellular cAMP in CHO human GPR119 stable cell line was measured using the LANCE Ultra cAMP Detection Kit (PerkinElmer). The assay was performed according to the manufacturer's protocol. Compounds were tested on CHO human GPR119 stable cell line. Cells were diluted in assay buffer (5 mM HEPES PH 7.4, Hank's Balanced Salt Solution, 0.1% BSA, 0.5 mM IBMX) and used at 2 × 10 3 cells/well in 384-well plates. Cells were incubated with compound for 60 min before addition of 5 μl 4× EucAMP tracer solution and 5 μl 4× ULight™-anti-cAMP solution. Signal = 665 nm Raw Data/615 nm Raw Data*10,000.
Min signal was obtained from the DMSO negative control (no compound, DMSO only).
Max signal was obtained from the action of referencepositive control GSK1292263 at 1 μM.
EC 50 was calculated using GraphPad Prism V5.0 software: Sigmoidal dose-response (variable slope). [18, 19] 
| Oral glucose tolerance test (OGTT) in normal mice
Synthesized compounds and positive control were formulated in 0.5% methylcellulose. Male ICR mice (18-22 g, were obtained from Shanghai SLAC Laboratory Animal Co. Ltd) were fasted overnight and randomly stratified (n = 6/group) to vehicle and test compound groups. Body weights were recorded on the morning of the study (postfasting) for dosevolume calculation. Blood samples were collected via the tail vein from all mice prior to dosing with either vehicle (0.5% methylcellulose) or test compound via oral gavage (100 mg/ kg). Thirty minutes later, mice were bled and immediately dosed with oral glucose (2 g/kg). The mice were rebled at 30, 60, and 120 min postglucose load. Glucose levels were measured on a SANNUO handheld monitor. AUC was calculated using GraphPad Prism 7 software. [20, 21] All animal experimental protocols were approved by the institutional committee at Jiangnan University and conducted according to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
| Oral glucose tolerance test (OGTT) in diabetic mice
Male ICR mice were acclimatized for 1 week and then treated with high-fat diet (HFD) (60% fat). After dietary treatments for a month, the mice were intraperitoneally injected with streptozotocin (STZ) (35 mg/kg/day) for 6 days. To validate that the type 2 diabetic mouse model was successfully established, fasting blood glucose levels in mice were assessed. The HFD-and STZ-treated mice with a fasting blood glucose level higher than 11 mmol/L were randomly subdivided into vehicle and test compound groups, and OGTT was performed in a manner similar to that described with normal mice. [22] 3 | RESULTS AND DISCUSSION
| Chemistry
The synthesis of this series of compounds started from reacting commercially available 2-bromo-5-hydroxypyridine (1) with N-Boc-protected piperidine alcohol to provide intermediate 2 over a Mitsunobu reaction (PPh 3 , DEAD, THF). 
| Biological activity
The ability of synthesized compounds to activate GPR119 receptor and stimulate increase in cAMP levels was evaluated using a cAMP activation assay in CHO cells stably expressing human GPR119. The results are shown in Table 1 , as well as ligand efficiency (LE), lipophilic ligand efficiency (LLE), and ligand efficiency dependent lipophilic (LELP) of the synthesized compounds 3-20. Our efforts were dedicated to maintaining or improving agonistic potency, while reducing lipophilicity, which is one of the most important physiochemical properties for druggability, by targeting lower LELP score. First, we studied the SAR of compound 3 (EC 50 = 83 nM, ClogP = 3.18, LELP = 9.94), which was substituted by tert-butyl carbamate in the N-position of piperidine. By removing the carbamate moiety (compound 4) or replacing it with amide groups (compound 11-13), the agonistic activity was diminished or even lost. It suggested that the piperidine carbamate region seemed to make pharmacologically very important H-bond with the receptor. [17] Switching from tert-butyl carbamate to isobutyl (compound 6, EC 50 = 180 nM, ClogP = 3. (EC 50 = 180 nM), it had LELP score (4.94) much lower than the positive compound MBX-2982 (8.69), which might imply a better chance of becoming drug candidates in the future. In order to assess the relevance of the cAMP assay results in vivo, we selected six compounds with better performances for profiling in a mouse OGTT at a fixed dose of 100 mg/ kg. The results were shown in Figure 3 , where significant glucose-lowering effects were observed. Compound 20 with the best performance in cAMP assays was the most efficacious one among all compounds tested, showing a significant decrease in glucose AUC, even better than the positive control MBX-2982. Compound 17 and compound 19 also showed significant glucose-lowering ability comparing to the blank group, at the same level with MBX-2982. Compound 15 did not show hypoglycemic effect as expected, might be connected to its low lipophilic (CLogP = 1.58), which led to low binding ability to protein. Compound 3 and compound 9 also failed the in vivo test, we speculated that ester linkage in these compounds was hydrolyzed in vivo and the hydrolysates generated had no activity. Based on the overall acceptable profile, we elected compound 19 to assess its ability to lower blood glucose level in type 2 diabetic mice induced by STZ and HFD, where we observed a significant reduction effect by compound 19 as well as MBX-2982 compared to vehicle control.
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| CONCLUSIONS
In summary, we have designed, synthesized, and characterized a series of novel 2-(4-(methylsulfonyl)phenyl)pyridine derivatives as GPR119 agonists. From the results of in vitro cAMP assays and LELP scores, compounds 3, 9, 17, 18, 19, and 20 performed potent agonistic activity with EC 50 values ranging from 25 to 95 nM, along with moderate lipophilic characteristics for improved druggability. Further OGTTs of these analogs led to the identification of compound 19, which effectively decreased blood glucose excursion and improved glucose tolerance in normal mice as well as diabetic mice. Additional characterization of these compounds in pharmacokinetic studies will be necessary to determine if they can represent a new type of antihyperglycemic agent for the effective treatment of T2DM. Furthermore, SAR research to discover more potent GPR119 agonists with diverse heterocyclic scaffolds is under progress. The evolution of these series of compounds will be reported in due course.
